Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Short term Debt (2017 - 2025)

Avanos Medical (AVNS) has disclosed Short term Debt for 8 consecutive years, with $10.2 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 8.51% to $10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 8.51% year-over-year, with the annual reading at $10.2 million for FY2025, 8.51% up from the prior year.
  • Short term Debt hit $10.2 million in Q4 2025 for Avanos Medical, up from $9.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $10.2 million in Q2 2024 to a low of $4.7 million in Q2 2022.
  • Historically, Short term Debt has averaged $8.1 million across 4 years, with a median of $9.4 million in 2024.
  • Biggest five-year swings in Short term Debt: skyrocketed 64.52% in 2024 and later dropped 7.84% in 2025.
  • Year by year, Short term Debt stood at $6.2 million in 2022, then soared by 38.71% to $8.6 million in 2023, then grew by 9.3% to $9.4 million in 2024, then grew by 8.51% to $10.2 million in 2025.
  • Business Quant data shows Short term Debt for AVNS at $10.2 million in Q4 2025, $9.4 million in Q3 2025, and $9.4 million in Q2 2025.